(Q38268342)

English

The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1 reference

Europe PubMed Central

The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

hypercholesterolemia

0 references

familial hypercholesterolemia

1 reference

based on heuristic

inferred from title

management recommendation

1 reference

based on heuristic

inferred from title

author name string

Anandita Agarwala

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Peter Jones

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Vijay Nambi

3

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

1 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Current Atherosclerosis Reports

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

467

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Diagnosis and treatment of familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Update on primary hypobetalipoproteinemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Other therapies for reducing low-density lipoprotein cholesterol: medications in development

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Targeting the androgen receptor in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Antisense oligonucleotides targeting parasite inositol 1,4,5-trisphosphate receptor inhibits mammalian host cell invasion by Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Prospects for nucleic acid-based therapeutics against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0467-4

21 January 2018

Oligonucleotide-based therapy for neurodegenerative diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antisense battles small molecule for slice of rare lipid disorder market

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipoprotein(a) and cardiovascular disease in heterozygous familial hypercholesterolemia: should we also blame the LDL receptor?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25398643

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11883-014-0467-4

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38268342&oldid=2201499817"